Astrazeneca Plc $AZN Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its position in Astrazeneca Plc (NYSE:AZN) by 6.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 142,455 shares of the company’s stock after acquiring an additional 8,147 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Astrazeneca were worth $25,001,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Brighton Jones LLC boosted its holdings in Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after acquiring an additional 11,690 shares during the last quarter. Amundi boosted its holdings in Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after acquiring an additional 3,618 shares during the last quarter. Jump Financial LLC boosted its holdings in Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after acquiring an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research reports. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Trading Up 0.0%

NYSE:AZN opened at $178.79 on Monday. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The firm has a market capitalization of $277.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The business’s 50-day moving average is $189.26 and its two-hundred day moving average is $186.07.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Research analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.